Adrienne Waks, MD, Dana-Farber Cancer Center, Boston, MA, discusses the evaluation of the HER2DX test's predictive value in neoadjuvant therapy for HER2-positive breast cancer. The study aimed to determine if HER2DX could predict the increase in pathological complete response (pCR) rates when a second anti-HER2 agent is added to trastuzumab-based chemotherapy and when multi-agent chemotherapy is used instead of a single agent taxane in the context of dual HER2 blockade. The analysis of four neoadjuvant cohorts demonstrated that HER2DX was significantly associated with pCR rates in all patients. Additionally, HER2DX identified patients who benefited most from dual HER2 blockade with chemotherapy or multi-agent chemotherapy. The findings suggest that HER2DX can help personalize treatment decisions for HER2-positive breast cancer patients. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
